SCHEMBL5775593

SCHEMBL5775593

CC(C)(C)OC(=O)N1CCC2(CCNCC2)CC1.CCOc1ccccc1CN1CCC2(CCNCC2)CC1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 9/20 0.57
USP2 O75604 4/20 0.57
TSHR P16473 2/20 0.52
CHRM2 P08172 1/20 0.50
CHRM3 P20309 1/20 0.50
CCR8 P51685 4/20 0.48
KCNH2 Q12809 4/20 0.48
CYP3A4 P08684 2/20 0.47
KDM4E B2RXH2 2/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 1/20 0.46
ALOX15 P16050 1/20 0.45
HTT P42858 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5307160 0.87 CCR8 (0.58) CYP2D6USP2TSHRCCR8KCNH2
SCHEMBL5436635 0.85 CYP2D6 (0.76) CYP2D6USP2TSHRCHRM2CHRM3
SCHEMBL4234286 0.81 CCR8 (0.65) CYP2D6USP2TSHRCCR8KCNH2
SCHEMBL4194050 0.80 CYP2D6 (0.69) CYP2D6USP2TSHRCCR8KCNH2
SCHEMBL5394015 0.77 CYP2D6 (0.68) CYP2D6USP2TSHRCHRM2CHRM3
SCHEMBL5400387 0.77 CYP2D6 (0.64) CYP2D6USP2TSHRCHRM2CHRM3
SCHEMBL118654 0.76 CYP1A2 (0.50) CYP2D6USP2SMN1; SMN2
SCHEMBL14371977 0.76 CYP2D6 (0.60) CYP2D6USP2TSHRCHRM2CHRM3
SCHEMBL12526355 0.76 CYP2D6 (0.69) CYP2D6USP2TSHRCHRM2CHRM3
Trifluoroacetic Acid SCHEMBL5431336 0.75 CCR8 (0.62) CYP2D6USP2TSHRCHRM2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1678178-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2006-07-12 EP disclosed
WO-2005040167-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2005-05-06 WO disclosed